Schulman IRB Partners with iMedRIS to Develop IBC Technology
Durham, NC & Redlands, CA - Schulman IRB, the industry-leading independent IRB in customer service and technology, announced today that iMedRIS Data Corporation, the fastest growing technology provider for optimizing research compliance and administration software, is developing the technology to power Schulman’s forthcoming institutional biosafety committee (IBC) service.
IBC clients and committee members will work from the same iMedRIS-developed platform, reducing duplicate data entry and the potential for errors while providing users with access to real-time information throughout the review process.
“We looked at a lot of options, and in the end we determined iMedRIS simply offers the best IBC software available,” said Daniel Eisenman, Biosafety Officer at Schulman IRB. “We’re able to easily customize the technology to our clients’ and committee members’ needs, and the system integrates well with our existing systems.”
For research involving human gene transfer (also known as gene therapy research), NIH Guidelines require a thorough risk assessment be performed by an IBC, along with institutional review board (IRB) review, for clinical trials to ensure the risks are identified and adequately mitigated.
Schulman’s forthcoming commercial IBC service will provide an independent option for research sponsors and institutions required to establish IBCs. The service will launch in the spring of 2017.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services in clinical quality assurance (CQA) and human research protections (HRP), and its commercial institutional biosafety committee (IBC) service will launch in Spring 2017. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA). For more information, please visit http://www.sairb.com or follow us on Twitter and LinkedIn.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
